Is CCNU (lomustine) valuable for treatment of cutaneous epitheliotropic lymphoma in dogs? A critically appraised topic

Aurore Laprais and Thierry Olivry

Abstract

Background: CCNU and other treatment protocols are commonly offered to owners for the treatment of dogs diagnosed with cutaneous (epitheliotropic) T-cell lymphoma (CTCL). Chemotherapy protocols provide variable benefits; they have different side-effects, and they typically require monitoring to detect drug toxicity at a non-negligible cost to the owner. At this time, even though CCNU is most often recommended to treat dogs with CTCL, there is no clear consensus on the benefit of this drug. Knowing which chemotherapy protocol yields the highest rate of complete remission and longest survival times would help veterinarians and pet owners select treatment options based on the best evidence available. Our objective was to review the literature to compare the complete remission rates and survival times of CCNU-based protocols to those of other interventions. We critically assessed the data included in articles reporting treatment outcome in at least five dogs with CTCL. Single case reports and case series with less than five patients were not reviewed to avoid anecdotal evidence of lower quality.

Results: The search for, and review and analysis of, the best evidence available as of February 8, 2017, suggests that CCNU and pegylated liposomal doxorubicin appear to yield the highest rate of complete remission in approximately one-third of dogs with CTCL. Other treatment protocols did not report usable information on remission rates. Without any treatment, the mean/median survival time in dogs with CTCL varied between 3 and 5 months. With CCNU protocols, the median survival time was 6 months and the one with retinoids (isotretinoin and/or etretinate), PEG L-asparaginase or prednisolone monotherapy was 11, 9 and 4 months, respectively; all these durations were obtained from small numbers of dogs, however.

Conclusions: CCNU leads to a complete remission of signs in approximately one-third of dogs with CTCL, but such remissions are of short duration. The median survival time after CCNU appears longer than that without treatment, but other drugs appear to provide a better long-term prognosis. Further studies are required to investigate the effect of CCNU, alone or in combination, on remission rates, survival times and impact on quality of life.

Keywords: Canine, Chemotherapy, Dog, Epitheliotropic, Lomustine, Lymphosarcoma, Mycosis fungoides, Neoplasia
Clinical scenarios
You have two patients: The first one is a 5-year-old female Labrador retriever crossbreed dog. The owners report that the lesions started 2.5 months beforehand and that they consisted, at first, of generalized scaling and pruritus. They evolved into multifocal areas of truncal alopecia and erythema along with an ulcer on the caudal abdomen. The dog was placed on a tapering course of prednisone that led to a reduction in clinical signs. After discontinuing the steroids, the dog developed alopecic erythematous macules, patches and plaques, and she became more pruritic than before.

Your second patient is a 12-year-old male golden retriever presenting with multifocal large patchy areas of hypopigmentation and depigmentation along with multifocal erythematous plaques and nodules. The owner reports that the dog may have had depigmented muzzle lesions for the past 2 years.

In both cases, skin biopsies confirmed your suspicion of CTCL. You wonder which chemotherapeutic option would be most beneficial for these two dogs.

Structured question
In a dog with CTCL, which chemotherapeutic treatment protocol would be most effective to induce the CR of clinical signs and to lead to the longest survival?

Methods
Search strategy
The CAB Abstracts and Web of Science (WoS) Science Citation Index Expanded databases were searched on April 26, 2016 for relevant articles using the following string: (dog or dogs or canine) and (cutaneous or epitheliotropic or epidermotropic) and (lymphoma or lymphosarcoma) and (CCNU or lomustine or vincristine or cyclophosphamide or chlorambucil or prednisone* or chemotherap*). The search was limited to the period 1980–2016. We then screened the bibliographies of identified articles for additional relevant reports. At the time of revision of this manuscript (February 08, 2017), a second broad literature search was done to identify papers published since the first search.

Results and discussion
Identified evidence
Our literature search found 63 and 65 articles in the CAB Abstract and Web of Science (WoS) databases, respectively. Citations were initially examined for the identification of articles reporting the outcome of treatment in dogs with CTCL diagnosed via histopathology. We then evaluated abstracts, and articles with potentially relevant information were read in full. The bibliography of these papers was analyzed further for additional pertinent reports.

We only selected articles that provided definite information on the rate of CR or survival times after diagnosis or treatment of at least five dogs with CTCL; articles and information on partial remission were not reviewed further.

Two retrospective [2, 3] and one prospective studies [4] providing clear information on CR rates in dogs with CTCL were found in both CAB and WoS databases. One preclinical trial [5] and one pilot study [6] were subsequently added following the review of the bibliographies of articles identified in the electronic searches. Finally, we added one last article that had been published after the performance of our initial literature search [7].

For survival times after diagnosis or treatment, one retrospective study [8] and one prospective study [9] were identified in the CAB abstracts, one of which was also found in the WoS [8]. A prospective [10] and a retrospective study [11] were added following the review of bibliographies of articles found in the electronic search.

Evaluation of evidence
Complete remission rates
The rates of CR in studies involving five or more dogs were given for protocols using CCNU, pegylated liposomal doxorubicin, the prodrug VDC-1101 (a guanine analog) and masitinib (Table 1).

Altogether, CCNU, alone or in conjunction with other concurrent medications, yielded a combined rate of CR of 30% of the 87 dogs reported [2, 3, 6]. The median duration of CR, estimated from only 15 dogs in one article [2], was 132 days (range: 26–258 days). The time to achieve CR was not identified in any article. In one report of 46 dogs [2], the overall median number of treatments needed to observe a response (type not specified) was one (range: one to six cycles).

A similar rate of CR occurred with pegylated liposomal doxorubicin, but the number of dogs treated (nine) was low [5]. The median duration of CR was shorter (90 days, range: 21–340) than with CCNU; the time to CR was not reported either.

The prednisone and VDC-1101 combination did not lead to CR in any of the ten dogs to which it was administered [4].

Finally, masitinib induced a CR of signs of CTCL in 2/10 treated dogs (20%); this remission lasted for 126 days in one dog and over 3 years in the other [7].

Survival times after diagnosis or treatment initiation
The survival times were only available for a few dogs treated with each intervention (Table 2). Without any treatment, the median survival time in dogs with CTCL varied between 3 [11] and 5 months [8].
The median/mean survival times were, in order of decreasing durations, 11 months after treatment with the retinoids isotretinoin and/or etretinate [9], 9 months after PEG L-asparaginase [10], 6 months after CCNU protocols [8] and 4 months after prednisolone alone [8].

Limitations

The main limitation of this compilation is that any confounding effect of the dog’s age, CTCL severity, CTCL stage or time before the diagnosis was made or treatment initiated were not evaluated for their possible impact on CR or survival times in any of these studies. Another limitation is that CCNU was used alone in only one-third of dogs in the largest case series [2, 3], and the rates of CR were not compared between dogs receiving CCNU monotherapy and those treated with combination regimens. Furthermore, the survival times provided were likely to have been influenced by euthanasia decisions by the owner, thereby not reflecting disease-induced death. Finally, many of the estimates provided herein were only assembled from a small number of patients.

Table 1 Rates of complete remission in dogs with CTCL

| References | CCNU | Pegylated liposomal doxorubicin | VDC-1101 and prednisone | Masitinib |
|------------|------|---------------------------------|-------------------------|-----------|
| N          | CR (N, %) | N            | CR (N, %) | N            | CR (N, %) | N            | CR (N, %) |
| Morges, 2014 [4] | 10 | 0 (0%) | | | | | |
| Risbon, 2006 [2] | 46 a | 15 (33%) | | | | | |
| Williams, 2006 [3] | 36 b | 6 (33%) | | | | | |
| Graham, 1999 [6] | 5 | 5 (100%) | | | | | |
| Vail, 1997 [5] | 9 | | 3 (33%) | | | | |
| Holtermann, 2016 [7] | 10d | | 2 (20%) | | | | |
| TOTAL | 87 | 26 (30%) | 9 | 3 (33%) | 10 | 0 (0%) | 1- | 2 (20%) |

Abbreviations: CR complete remission, N number of dogs

a 14 dogs received CCNU monotherapy, 27 also received glucocorticoids that were later either tapered, discontinued or maintained. The co-administration of prednisone was not reported to be significantly associated with the response or its duration. Other concurrent medications included PEG L-asparaginase (6 dogs), essential fatty acids (8), nonsteroidal anti-inflammatory drugs (3), retinoids (2), and interferon (1)

b 67% of the dogs experiencing a CR also received concurrent glucocorticoids

c 2 dogs may have received concurrent surgery

d the response was assessed on the three most dominant “target” lesions

Conclusions

Implications for practitioners

In spite of the limitations raised above, and taking into consideration the best evidence available, CCNU protocols, when used alone or in combination with other drugs, appear to lead to CR rates of 30%, but the median duration of such CRs remains unclear. The median survival time of CTCL after CCNU protocols is 6 months following diagnosis. Retinoids or PEG L-asparaginase appear to offer longer median survival times, but these drugs are not routinely available.

At the time of this writing, CCNU—alone or in combination with other drugs—appears to be a valuable option to treat dogs with CTCL; unfortunately, the common occurrence of myelopoietic and/or gastrointestinal side effects requires frequent blood test monitoring that increases the cost of treatment.

Implication for research

Additional studies are needed to compare the rates of CR and survival times using glucocorticoids, CCNU or retinoids (e.g. bexarotene), either alone or in various

Table 2 Survival times in dogs with CTCL (in months)

| References | CCNU | Prednisolone | Retinoids a | PEG L-asparaginase b | No treatment |
|------------|------|--------------|-------------|---------------------|-------------|
| N          | S    | N            | S           | N                   | S           |
| Fontaine, 2010 [8] | 7 | 6 | 6 | 4 | |
| White, 1993 [9] | | | | 5 | 11 |
| Moriello, 1993 [10] | | | | 7 | 9 |
| Beale, 1993 [11] | | | | | 8 | 3 |

Abbreviations: N number, S median or mean survival times (in months) after diagnosis or treatment

a the concurrent use of glucocorticoids was allowed

b three patients also received glucocorticoids, one patient was also treated with vincristine/cyclophosphamide and doxorubicin

c most dogs were euthanized; the specific number of dogs was not specified

d all dogs were euthanized

e the number of dogs euthanized was not specified
combinations thereof. Because of the potential toxicity and side effects of CCNU, the quality of life in dogs receiving CCNU protocols should be compared to that without any treatment or with other medications. Future studies should also attempt to compare CR rates and survival times in dogs of various age groups as well as in those with variable duration of clinical signs, stages or severities of CTCL.

Abbreviations

CCNU: 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (i.e. lomustine); CR: complete remission; CTCL: cutaneous T-cell lymphoma; PEG, polyethylene glycol

Acknowledgement

None needed.

Funding

None.

Availability of data and materials

The data analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

The two authors selected the topic of this CAT; AFL performed the literature search, extracted and summarized the evidence; TO verified the evidence and both authors contributed to the writing of this article.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not needed or relevant.

Ethics approval and consent to participate

Not needed or relevant.

Received: 12 November 2016 Accepted: 15 February 2017
Published online: 21 February 2017

References

1. Heading KL, Brockley LK, Bennett PF. CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07). Aust Vet J. 2011;89:109–16.
2. Risbon NE, de Lorimier LP, Skorupski K, Burgess KE, Bergman PJ, Carreras J, Hahn K, Leblanc A, Turk K, Impellizzeri F, Fred 3rd R, Wojcieszyn JW, Drobatz K, Clifford CA. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999-2004). J Vet Intern Med. 2006;20:1389–97.
3. Williams LE, Rassnick KM, Power HT, Luna SE, Morrison-Collister KE, Hansen K, Johnson JL. CCNU in the treatment of canine epitheliotropic lymphoma. J Vet Intern Med. 2006;20:136–43.
4. Morges MA, Burton JH, Saba CF, Vail DM, Burgess KE, Thamm DH. Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma. J Vet Intern Med. 2014;28:1569–74.
5. Vail DM, Kravis LD, Cooley AJ, Chun R, MacEwen EG. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol. 1997;39:410–6.
6. Graham JC, Myers RK. Pilot study on the use of lomustine (CCNU) for the treatment of cutaneous lymphoma in dogs [abstract 125]. Proceedings of the Proceedings of the 17th Annual Forum of the College of Veterinary Internal Medicine. Chicago: American College of Veterinary Internal Medicine; 1999.
7. Holtermann N, Kupel M, Kessler M, Teske E, Betz D, Hirschberger J. Masitinib monotherapy in canine epitheliotropic lymphoma. Vet Comp Oncol. 2016;14 Suppl 1:127–35.
8. Fontaine J, Heimann M, Day MJ. Canine cutaneous epitheliotropic T-cell lymphoma: a review of 30 cases. Vet Dermatol. 2010;21:267–75.
9. White SD, Rosychuk RA, Scott KV, Trettien AL, Jonas L, Denerolle P. Use of isotretinoin and etretinate for the treatment of benign cutaneous neoplasia and cutaneous lymphoma in dogs. J Am Vet Med Assoc. 1993;202:387–91.
10. Moriello KA, MacEwen G, Schultz KT. Peg-L-asparaginase in the treatment of canine epitheliotropic lymphoma and histiocytic proliferative dermatitis. In: Ihrke PJ, Mason IS, White SD, editors. Advances in veterinary dermatology, vol. 2. 1993, p. 293–9.
11. Beale KM, Bolon B. Canine cutaneous lymphosarcoma: epitheliotropic and non-epitheliotropic, a retrospective study. In: Ihrke PJ, Mason IS, White SD, editors. Advances in veterinary dermatology, vol. 2. New York: Pergamon Press; 1993. p. 273–84.